World Equity Group Inc. Acquires Shares of 2,420 Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

World Equity Group Inc. acquired a new stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 2,420 shares of the medical equipment provider’s stock, valued at approximately $256,000.

Other hedge funds also recently bought and sold shares of the company. Dunhill Financial LLC raised its holdings in Zimmer Biomet by 1,090.0% in the 3rd quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider’s stock valued at $26,000 after acquiring an additional 218 shares during the last quarter. Stonebridge Financial Group LLC acquired a new stake in Zimmer Biomet in the 4th quarter valued at about $25,000. Ashton Thomas Securities LLC acquired a new stake in Zimmer Biomet in the 3rd quarter valued at about $28,000. Brooklyn Investment Group acquired a new stake in Zimmer Biomet in the 3rd quarter valued at about $35,000. Finally, Kentucky Trust Co acquired a new stake in Zimmer Biomet in the 4th quarter valued at about $39,000. Institutional investors and hedge funds own 88.89% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have commented on ZBH shares. Wells Fargo & Company increased their price objective on shares of Zimmer Biomet from $110.00 to $117.00 and gave the company an “equal weight” rating in a report on Thursday, October 31st. Barclays dropped their price target on shares of Zimmer Biomet from $118.00 to $112.00 and set an “underweight” rating for the company in a research note on Monday, February 10th. Truist Financial reissued a “hold” rating and issued a $113.00 price target (down previously from $118.00) on shares of Zimmer Biomet in a research note on Monday, February 10th. Needham & Company LLC reissued a “hold” rating on shares of Zimmer Biomet in a research note on Friday, February 7th. Finally, JPMorgan Chase & Co. raised shares of Zimmer Biomet from a “neutral” rating to an “overweight” rating and increased their price target for the company from $125.00 to $128.00 in a research note on Tuesday, December 17th. Two equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat.com, Zimmer Biomet currently has a consensus rating of “Hold” and a consensus price target of $124.15.

Zimmer Biomet Stock Performance

Shares of ZBH stock opened at $106.00 on Tuesday. The firm has a 50 day moving average of $105.85 and a two-hundred day moving average of $107.44. The stock has a market capitalization of $21.10 billion, a PE ratio of 23.82, a P/E/G ratio of 1.95 and a beta of 1.02. The company has a quick ratio of 0.99, a current ratio of 1.91 and a debt-to-equity ratio of 0.43. Zimmer Biomet Holdings, Inc. has a 52 week low of $97.69 and a 52 week high of $133.90.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 EPS for the quarter, topping the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. During the same period in the prior year, the business earned $2.20 earnings per share. On average, research analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, January 31st. Shareholders of record on Monday, December 30th were paid a $0.24 dividend. The ex-dividend date of this dividend was Monday, December 30th. This represents a $0.96 annualized dividend and a dividend yield of 0.91%. Zimmer Biomet’s dividend payout ratio (DPR) is 21.57%.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.